Maternal Lopinavir/Ritonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir

Table 4

Infant adverse events at 4 weeks associated with exposure to maternal lopinavir/ritonavir versus nelfinavir or atazanavir.

Laboratory test	Lopinavir/ritonavir	Nelfinavir	Odds ratio (95% CI); value	Atazanavir	Odds ratio (95% CI); value
Hgb	19/53 (36%)	14/34 (41%)	1.3 (0.52–3.0)	6/14 (43%)	1.3 (0.41–4.4)
ANC	24/48 (50%)	11/30 (37%)	0.58 (0.23–1.5)	5/14 (36%)	0.56 (0.16–1.9)
Bili	11/52 (21%)	9/26 (35%)	2.5 (0.75–8.1)	3/7 (43%)	2.0 (0.35–11.4)
Highest grade AE, all tests	38/55 (69%)	22/35 (63%)	0.76 (0.31–1.8)	9/14 (64%)	0.62 (0.16–2.4)

Hgb, hemoglobin; ANC, absolute neutrophil count; Bili, total bilirubin; AE, adverse event.
Multivariate analysis using logistic regression was used to model grade ≥1 AE (yes/no) as a function of maternal antiretroviral treatment. No significant differences were found.
There were no adverse events for alanine aminotransferase, 1 adverse event each for aspartate aminotransferase in the lopinavir/ritonavir and atazanavir groups, and 1 adverse event for platelet count in each group, not shown separately but included in the maximum adverse events.
Number of adverse events/number exposed (%).
Lopinavir/ritonavir versus nelfinavir.
Lopinavir/ritonavir versus atazanavir.